The January 2025 Head Start webinar explored the UNITE study, A multi-centre, double-blind, placebo-controlled, parallel-group, clinical trial followed by an open-label extension to evaluate the efficacy and safety of fremanezumab for the preventive treatment of migraine in patients with Major Depressive Disorder. This study was designed to assess patients with migraine and comorbid depressive disorder to demonstrate the potential of anti-CGRP addressing migraine and psychiatric comorbidities in a complex patient populations.1
Discover the key insights from the UNITE study in this Head Start webinar! Listen to the short video led by Dr Giorgio Lambru as he explains the outcomes resulting in significant reductions in migraine days, improvements in depression scores, and strong tolerability—showing the potential of anti-CGRP therapy to transform care for complex cases. Watch now to explore the migraine anxiety & depression cycle: CGRP inhibitors help break it?
